Altimmune Other Liab from 2010 to 2024

ALT Stock  USD 8.25  0.07  0.86%   
Altimmune Other Liabilities yearly trend continues to be comparatively stable with very little volatility. Other Liabilities will likely drop to about 3.3 M in 2024. From the period from 2010 to 2024, Altimmune Other Liabilities quarterly data regression had r-value of  0.50 and coefficient of variation of  126.88. View All Fundamentals
 
Other Liabilities  
First Reported
2014-12-31
Previous Quarter
3.7 M
Current Value
M
Quarterly Volatility
5.5 M
 
Yuan Drop
 
Covid
Check Altimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altimmune's main balance sheet or income statement drivers, such as Interest Expense of 33.2 K, Selling General Administrative of 13.5 M or Total Revenue of 404.7 K, as well as many indicators such as Price To Sales Ratio of 1.5 K, Dividend Yield of 0.0 or PTB Ratio of 3.24. Altimmune financial statements analysis is a perfect complement when working with Altimmune Valuation or Volatility modules.
  
Check out the analysis of Altimmune Correlation against competitors.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

Latest Altimmune's Other Liab Growth Pattern

Below is the plot of the Other Liab of Altimmune over the last few years. It is Altimmune's Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Altimmune's overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

Altimmune Other Liab Regression Statistics

Arithmetic Mean2,358,180
Geometric Mean924,414
Coefficient Of Variation126.88
Mean Deviation2,368,977
Median330,541
Standard Deviation2,992,011
Sample Variance9T
Range9.7M
R-Value0.50
Mean Square Error7.3T
R-Squared0.25
Significance0.06
Slope331,462
Total Sum of Squares125.3T

Altimmune Other Liab History

20243.3 M
20234.5 M
20223.9 M
2021330.5 K
20207.2 M
20193.1 M
20181.4 M

About Altimmune Financial Statements

Altimmune shareholders use historical fundamental indicators, such as Other Liab, to determine how well the company is positioned to perform in the future. Although Altimmune investors may analyze each financial statement separately, they are all interrelated. The changes in Altimmune's assets and liabilities, for example, are also reflected in the revenues and expenses on on Altimmune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Liabilities4.5 M3.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.